Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379275 · ClinicalTrials.gov registry record
Eye and Immunogenetic Features of Sarcoidosis
A clinical trial, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 100
- Enrollment target
NCT00379275 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 100 participants.
The verdict
NCT00379275 has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This study will evaluate patients with sarcoidosis to understand how the disease affects the body. Sarcoidosis is a disease that results from inflammation of body tissues. The lungs, lymph nodes in the chest, skin and eyes are most commonly affected. As the disease progresses, small lumps, or granulomas, appear in the affected tissues. In most cases, the granulomas clear up, but in cases where they do not heal and disappear, the tissues tend to remain inflamed. Eye inflammation (uveitis) associated with sarcoidosis can cause various eye diseases, sometimes leading to blindness. This study will examine the clinical, immunological and genetic features of ocular sarcoidosis. Patients 6 years of age and older with sarcoidosis may be eligible for this study. Candidates are screened with the following procedures: * Completion of a questionnaire with medical, social and demographic information * Blood draw for laboratory tests * Complete eye examination, including measurement of eye pressure and dilation of the pupils to examine the back of the eye. Fluorescein angiography may be done. This test involves injecting a dye into a vein in the arm. The dye travels to the blood vessels in the eyes. A camera flashes a blue light into the eye and takes pictures of the retina that show whether the dye has leaked from the blood vessels into the retina. Other photographs of the eye may also be taken using a special camera. Participants are followed in conjunction with their local eye doctor as required by the status of their disease. Patients whose disease is stable are seen for an initial examination and followed every 12 months for 3 years.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-09-18 |
| Est. Completion | 2007-12-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00379275
The ClinicalTrials.gov registry entry for NCT00379275 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00379275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00379275 about?
NCT00379275 is a clinical study titled "Eye and Immunogenetic Features of Sarcoidosis". This study will evaluate patients with sarcoidosis to understand how the disease affects the body. Sarcoidosis is a disease that results from inflammation of body tissues. The lungs, lymph nodes in the chest, skin and eyes are most commonly affected. As the disease progresses, small lumps, or granul...
What is the current status of trial NCT00379275?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2006-09-18. Estimated completion is 2007-12-10.
Who is sponsoring clinical trial NCT00379275?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.